Paul A Bunn Jr, MD Professor and Director University of Colorado Cancer Center James Dudley Chair in Cancer Research Denver, Colorado
	Click here to download entire interview
Track 1	Selection of front-line chemotherapy for advanced non-small cell lung cancer (NSCLC)
Track 2	Clinical use of bevacizumab for advanced NSCLC
Track 3	Continuation of bevacizumab after disease progression
Track 4	Hemoptysis and bevacizumab
Track 5	Pemetrexed in combination with bevacizumab
Track 6	Options for second-line therapy for advanced NSCLC
Track 7	Development of nanoparticle albumin-bound (nab) paclitaxel in NSCLC
Track 8	Incidence of lung cancer in never smokers and oligosmokers
Track 9	Clinical and molecular predictors of response to tyrosine kinase inhibitors (TKIs)
Track 10	Assessment of molecular predictors of response to TKIs
Track 11	SWOG-S0342: EGFR positivity by FISH and response to cetuximab
Track 12	Potential role for the dual EGFR-VEGFR inhibitor vandetanib (ZD6474) in NSCLC
Track 13	RADIANT: Erlotinib with or without prior adjuvant chemotherapy for patients with NSCLC and EGFR-positive tumors
Track 14	ECOG-E1505: Adjuvant chemotherapy with or without bevacizumab for Stage IB to IIIA NSCLC
Track 15	Adjuvant therapy for patients with Stage IB NSCLC
Track 16	Selection of an adjuvant chemotherapy regimen on E1505
Track 17	MAGE3: GSK1572932A antigen-specific immunotherapeutic as adjuvant therapy for MAGE-A3- positive NSCLC
Track 18	Future prospects in early detection and treatment of lung cancer

Nasser H Hanna, MD Associate Professor Department of Medicine Division of Hematology/Oncology School of Medicine Indiana University Medical Center Indianapolis, Indiana
	Click here to download entire interview
Track 1	ECOG-E1505: Adjuvant chemotherapy with or without bevacizumab for Stage IB to IIIA NSCLC
Track 2	Adverse prognostic factors in Stage IB NSCLC
Track 3	Selection of an adjuvant chemotherapy regimen
Track 4	AVAiL: Bevacizumab (7.5 versus 15 mg/kg) with cisplatin/gemcitabine for chemotherapy-naïve patients with advanced or recurrent nonsquamous NSCLC
Track 5	Risk and benefit tradeoffs of bevacizumab in the adjuvant setting
Track 6	Duration of adjuvant bevacizumab in E1505
Track 7	Research strategies to identify populations sensitive to EGFR TKIs
Track 8	Exploring new clinical research strategies with chemoradiation therapy and targeted therapy in lung cancer
Track 9	HOG LUN 01-24: Cisplatin/etoposide and concurrent radiation therapy with or without consolidation docetaxel for inoperable Stage III NSCLC
Track 10	Toxicity of consolidation docetaxel in HOG LUN 01-24
Track 11	Relationship between number of adjuvant chemotherapy cycles and clinical benefit in Stage III NSCLC
Track 12	Combined anti-angiogenic strategies in lung cancer with bevacizumab and enzastaurine
Track 13	Emerging clinical trial data and clinical experience with sorafenib in lung cancer
Track 14	Novel agents in development in lung cancer
Track 15	Clinical trial results with the oral EGFR and VEGFR TKI vandetanib in lung cancer
Track 16	NCI Canada BR.20: Maintenance vandetanib for patients with small cell lung cancer (SCLC) who have a complete or partial response to induction therapy
Track 17	Clinical trial data with the EGFR monoclonal antibody cetuximab in lung cancer
Track 18	Clinical algorithm for treatment of advanced NSCLC

Antoinette J Wozniak, MD Professor of Medicine and Oncology Leader, Thoracic Multidisciplinary Team Karmanos Cancer Institute Wayne State University Detroit, Michigan
	Click here to download entire interview
Track 1	Use of cisplatin versus carboplatin in adjuvant therapy regimens
Track 2	Rationale for using adjuvant cisplatin/docetaxel
Track 3	Clinical management of Stage IA NSCLC
Track 4	ERCC1 and response to cisplatin in IALT
Track 5	Clinical algorithm for treatment of unresectable Stage III NSCLC
Track 6	SWOG-S0533: Chemoradiation therapy and bevacizumab for newly diagnosed, unresectable Stage III NSCLC
Track 7	Clinical management of potentially resectable Stage III NSCLC
Track 8	Evolving role of pemetrexed in NSCLC
Track 9	Phase II study of pemetrexed, gemcitabine and bevacizumab for chemotherapy-naïve patients with Stage IIIB or IV nonsquamous NSCLC
Track 10	Phase III study of pemetrexed/cisplatin versus gemcitabine/cisplatin for chemotherapy-naïve patients with locally advanced or metastatic NSCLC
Track 11	Erlotinib as a single agent or intercalated with combination chemotherapy for patients with newly diagnosed advanced NSCLC and EGFR-positive tumors
Track 12	Controversial issues in the clinical use of bevacizumab for NSCLC
Track 13	First-line therapy for never smokers or oligosmokers
Track 14	Gender and response to bevacizumab
Track 15	SWOG-S0635: Erlotinib and bevacizumab for Stage IIIB or IV bronchoalveolar carcinoma (BAC) or adenocarcinoma with BAC features
Track 16	Development of the multikinase inhibitor vandetanib in NSCLC
Track 17	Prophylactic cranial irradiation (PCI) versus no PCI in extensive-disease SCLC after response to chemotherapy